CanSino Biologics, Inc. Class H (6185) AI Stock Analysis

• Market Cap: HK$10.89B
• Dividend Yield: N/A
• Average Volume (3M): 1.16M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.61
• Revenue Growth: 94.98%
• EPS Growth: 85.69%
• Country: HK
• Employees: 1,105
• Sector: Healthcare
• Sector Strength: 44
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.96
• Shares Outstanding: 132,670,900
• 10 Day Avg. Volume: 1,116,950
• 30 Day Avg. Volume: 1,164,804
• PEG Ratio: 0.10
• Price to Book (P/B): 2.16
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: HK$34.00 ▼(-3.82%Downside)

The most significant factor is the company's poor financial performance, which severely impacts the overall score. Technical analysis provides some positive signals, indicating potential for short-term gains. However, the unfavorable valuation due to negative earnings and lack of dividends further weighs down the score. Improving financial health is crucial for a better outlook.

CanSino Biologics, Inc. Class H Business Overview & Revenue Model

Company Description

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

How the Company Makes Money

CanSino Biologics makes money primarily through the sale of its vaccine products to governments, healthcare organizations, and distributors. Revenue streams include direct sales of vaccines, partnerships with governments for vaccine distribution, and potentially licensing agreements for vaccine technologies. The company also engages in research collaborations and partnerships that may contribute to its revenue. In particular, the global demand for COVID-19 vaccines has been a significant factor in its recent earnings, with CanSino's COVID-19 vaccine being distributed in several countries.

CanSino Biologics, Inc. Class H Financial Statement Overview

Summary

CanSino Biologics is facing significant financial challenges. Declining revenues and profitability, with ongoing operational and net losses, are concerning. Despite a strong equity position, the increasing debt-to-equity ratio and negative cash flows raise financial sustainability concerns. Improving operational efficiency and revenue generation is critical.

Income Statement

CanSino Biologics showed a significant decline in revenue and profitability over the past few years. The company had a positive revenue growth in 2024, but it still incurred a net loss. Gross profit margins are positive in 2024, but the net profit margin remains deeply negative due to high operating losses. The company's EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The balance sheet shows a relatively high level of equity compared to total assets, indicating financial stability. However, the debt-to-equity ratio has increased, which could pose a risk if revenue and profitability do not improve. The company's return on equity is negative due to ongoing losses, but it still maintains a solid equity base.

Cash Flow

The cash flow statement reflects challenges in generating cash from operations, with negative operating and free cash flow. The free cash flow growth rate is negative, which is concerning for long-term sustainability. The company is investing heavily, which may benefit future growth if managed efficiently.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
846.34M	345.18M	1.03B	4.30B	18.54M
	Gross Profit
601.91M	-876.02M	-186.61M	3.00B	4.74M
	EBIT
-375.22M	-2.04B	-1.37B	1.91B	-440.32M
	EBITDA
-134.84M	-1.65B	-1.03B	1.98B	-402.97M
	Net Income Common Stockholders
-378.88M	-1.48B	-964.76M	1.91B	-358.49M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.20B	4.12B	5.95B	7.78B	5.11B
	Total Assets
7.96B	9.32B	11.47B	11.87B	6.75B
	Total Debt
2.01B	2.70B	2.70B	1.37B	142.54M
	Net Debt
456.91M	653.34M	-694.19M	-4.08B	-4.30B
	Total Liabilities
3.05B	4.03B	4.22B	3.33B	677.22M
	Stockholders Equity
4.91B	5.27B	6.75B	8.00B	6.07B
Cash Flow		Free Cash Flow
-626.42M	-1.53B	-2.96B	811.42M	-740.16M
	Operating Cash Flow
-168.79M	-916.25M	-1.89B	2.01B	-469.39M
	Investing Cash Flow
3.96M	-449.65M	-1.19B	-2.53B	-182.71M
	Financing Cash Flow
-334.18M	-7.58M	854.60M	1.56B	4.94B

CanSino Biologics, Inc. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 35.35
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6185, the sentiment is Positive. The current price of 35.35 is above the 20-day moving average (MA) of 33.70, above the 50-day MA of 32.30, and above the 200-day MA of 29.38, indicating a bullish trend. The MACD of 0.79 indicates Negative momentum. The RSI at 61.65 is Neutral, neither overbought nor oversold. The STOCH value of 87.10 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6185.

CanSino Biologics, Inc. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
6185	48 Neutral	HK$10.89B	―	-4.41%	―	94.98%	85.69%
SBMFF		$10.87B	46.27	6.14%	1.22%	―	―
SHTDF		$7.57B	6.95	9.19%	5.60%	―	―
TRSBF		$7.33B	27.80	14.19%	1.03%	―	―
WXIBF		$13.76B	26.06	8.17%	―	―	―
1873	59 Neutral	HK$3.85B	21.45	4.47%	―	-9.75%	―

CanSino Biologics, Inc. Class H Corporate Events

CanSino Biologics Gains Approval for Inhaled TB Vaccine Trial in Indonesia

CanSino Biologics Inc. announced the approval of its Phase I clinical trial for an inhaled tuberculosis booster vaccine in Indonesia. This development is significant as it addresses the limitations of the existing Bacillus Calmette-Guerin vaccine by offering a booster that enhances mucosal immunity, potentially improving tuberculosis prevention efforts in high-burden regions.

CanSino Biologics Sets Agenda for 2024 AGM with Key Resolutions

CanSino Biologics Inc. has announced the agenda for its 2024 Annual General Meeting, scheduled for June 4, 2025, in Tianjin, China. The meeting will cover several key resolutions, including the approval of the 2024 financial reports, profit distribution plans, and reappointment of auditors. Additionally, shareholders will consider granting mandates for share issuance and repurchase, which could impact the company’s capital structure and market operations.

CanSino Biologics Reports Q1 2025 Financial Results with Increased Revenue

CanSino Biologics Inc. reported its unaudited financial results for the first quarter of 2025, showing a 20.02% increase in operating revenue compared to the same period last year. Despite the revenue growth, the company experienced a net loss attributable to shareholders, although significantly reduced from the previous year’s loss, indicating a potential improvement in financial health. The report highlights the company’s ongoing challenges in achieving profitability, yet suggests a positive trend in revenue generation.

CanSino Biologics to Review Q1 2025 Results in Upcoming Board Meeting

CanSino Biologics Inc. has announced an upcoming board meeting scheduled for April 29, 2025, where the board will review and approve the company’s first quarterly results for the period ending March 31, 2025. This meeting is significant as it will provide insights into the company’s financial performance and operational progress, potentially impacting its market positioning and stakeholder confidence.

CanSino Biologics Releases 2024 Annual Results

CanSino Biologics Inc. has announced its audited consolidated annual results for the year ending December 31, 2024. The results, which comply with the Hong Kong Stock Exchange’s listing requirements, have been reviewed and confirmed by the company’s board and audit committee. The annual report will be available to shareholders and on relevant websites, reflecting the company’s commitment to transparency and regulatory compliance.

CanSino Biologics to Announce 2024 Annual Results and Dividend Consideration

CanSino Biologics Inc. has announced a board meeting scheduled for March 25, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the recommendation of a final dividend payment, reflecting the company’s financial performance and potential shareholder returns.